结肠支架单独和新辅助化疗对左侧阻塞性结肠癌患者的比较有效性:一个元分析
Qin Sun1,2, Xinyi Zhang3, Jiani You3
1Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
International journal of surgery (London, England)
|July 28, 2025
概括
结肠支架与新辅助化疗 (CS-NAC) 结合,与结肠支架 (CS) 后的选择性手术相比,改善了左侧阻塞性结肠癌的短期结果和生存率. CS-NAC不会增加特定不良事件的风险.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 手术瘤学手术瘤学
背景情况:
- 急性左侧阻塞性结肠癌 (LSOCC) 的管理存在重大挑战.
- 两个主要的治疗策略包括选择性手术后结肠支架 (CS) 和结肠支架结合新辅助化疗 (CS-NAC).
研究的目的:
- 为了比较LSOCC的CS与CS-NAC的短期和长期结果.
- 评估这两种治疗方法的疗效和安全性.
主要方法:
- 一项对2000年1月至2025年5月期间发表的七项研究的元分析.
- 在PubMed和Web of Science进行文献搜索.
- 计算了聚合赔率比率,平均差异和95%置信区间.
主要成果:
- 与CS相比,CS-NAC表现出优越的短期结果,包括较高的腹腔镜手术率,减少手术内静脉瘤率,较少的不良事件,较短的手术时间,以及减少住院时间.
- 在与支架相关的并发症或特定不良事件 (如感染或静脉漏) 中没有发现显著差异.
- CS-NAC显著改善了3年无病生存率和整体生存率.
结论:
- CS-NAC策略提高了腹腔镜手术率和LSOCC的3年生存率.
- 与单独使用CS相比,这种方法不会增加特定术后并发症的风险.
更多相关视频
03:43Structured Approach to Colonoscopy Technique Optimization: A Single-Center Experience with Novice Endoscopists
Published on: July 11, 2025
147
08:26Clinical Application of Single-Surgeon, Three-Port, Laparoscopic Resection for Colorectal Cancer with Natural Orifice Specimen Extraction
Published on: March 24, 2023
637
相关概念视频
Inflammatory Bowel Disease V: Surgical Management
217
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
217
Endoscopic Procedures II: Colonoscopy
192
The colon, or large intestine, is the final segment of the digestive system. Its primary functions include absorbing water and vitamins produced by gut bacteria and transforming waste from liquid to solid to form stool. In adults, the large intestine is approximately 5 feet long and consists of four main sections:
192
Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239
